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Introduction:  Early  inﬂammatory  bowel  disease  (IBD)  diagnosis  remains  a clinical  challenge.  Volatile
organic  compounds  (VOCs)  have  shown  distinct  patterns  in  Crohn’s  disease  (CD)  and  ulcerative  col-
itis (UC).  VOC  production,  reﬂecting  gut  fermentome  metabolites,  is  perturbed  in IBD.  VOC  sampling
is  non-invasive,  with  various  compounds  identiﬁed  from  faecal,  breath  and  urine  samples.  This  study
aimed  to determine  if FAIMS  (ﬁeld  asymmetric  ion  mobility  spectroscopy)  analysis  of  exhaled  VOCs
could  distinguish  IBD  from  controls.
Methods:  Seventy-six  subjects  were  recruited,  54  established  IBD  (25 CD, 29  UC) and 22 healthy  con-
trols.  End  expiratory  breath  was captured  using  a Warwick  device  and  analysed  by  FAIMS.  Data  were
pre-processed  using  wavelet  transformation,  and  classiﬁcation  performed  in  a 10-fold  cross-validation.
Feature  selection  was performed  using  Wilcoxon  rank sum  test,  and  sparse  logistic  regression  gave  class
predictions,  to calculate  sensitivity  and  speciﬁcity.
Results: FAIMS  breath  VOC  analysis  showed  clear  separation  of  IBD  from  controls,  sensitivity:  0.74
(0.65–0.82),  speciﬁcity:  0.75  (0.53–0.90),  AUROC:  0.82  (0.74–0.89),  p-value  6.2 × 10−7.  IBD  subgroup  anal-
ysis  distinguished  UC  from  CD:  sensitivity  of  0.67  (0.54–0.79),  speciﬁcity:  0.67  (0.54–0.79),  AUROC:  0.70
(0.60–0.80),  p-value  9.23  ×  10−4.
Conclusion:  This  conﬁrms  the utility  of exhaled  VOC  analysis  to  distinguish  IBD from  healthy  controls,
and  UC  from  CD.  It conforms  to other  studies  using  different  technology,  whilst  afﬁrming  exhaled  VOCs
as biomarkers  for diagnosing  IBD.
 Gast© 2015  Editrice
. Introduction
Inﬂammatory bowel disease (IBD) is a common condition affect-
ng the Western world with approximately 115,000 people in the
K suffering from Crohn’s disease (CD) and 146,000 with ulcer-
tive colitis (UC) [1,2]. The pathogenesis of IBD is not entirely
nderstood, but widely believed to be the result of complex interac-
ions between an individual’s genetic susceptibility, environmental
∗ Corresponding author at: Clinical Sciences Research Institute, Univer-
ity of Warwick, Clifford Bridge Road, Coventry CV2 2DX, United Kingdom.
el.: +44 02476 966098; fax: +44 02476 966090.
E-mail address: r.arasaradnam@warwick.ac.uk (R.P. Arasaradnam).
ttp://dx.doi.org/10.1016/j.dld.2015.10.013
590-8658/© 2015 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Allroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  All  rights  reserved.
triggers (e.g. diet, life style, etc.) and the inﬂuence of an individual’s
gastrointestinal bacterial colonies [3]. Bacterial diversity is prob-
lematic to study, as <50% of organisms can be successfully cultured
and modern genomic techniques, though far more successful, are
too expensive and impractical for every day clinical use [3].
Current diagnostic tools for IBD include a thorough history,
faecal inﬂammatory markers, endoscopic investigations with his-
tological examination, capsule endoscopy and imaging. Despite the
diverse array of investigations available, the diagnosis of CD or UC
can often be difﬁcult when disease is limited to the colon, and may
rely on histology. Even so, the accepted standard of histology can
often fail to distinguish between CD from UC.
The detection of patterns of volatile organic compounds (VOCs)
and their utility as disease speciﬁc gas phase biomarkers has been a
 rights reserved.
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Table  1
Demographic data of inﬂammatory bowel disease (IBD) patients and healthy controls.
Disease Crohn’s disease (n = 25) Ulcerative colitis (n = 29) Controls (n = 22)
Mean age in years (SD) 43.7 (14.9) 47.9 (15.5) 41.2 (13.5)
Gender ratio (M:F) 11:14 9:20 2:20
Smoking – mean cigarettes/day (SD) 2.8 (5.6) 0.8 (2.9) 1.3 (2.6)
Alcohol – mean units/week (SD) 3.3 (5.0) 3.6 (5.2) 6.0 (7.2)
Mean  BMI  (SD) 27.7 (6.5) 25.8 (5.4) 25.6 (4.0)
Medications 5 ASA: 15 5 ASA: 23 Salbutamol (inhaled): 3
AZA/MP: 6 AZA/6MP: 5 Levothyroxine: 2
Anti-TNF:  3 Anti-TNF: 2
Oral steroids: 1 Oral steroids: 1
PPI: 2 PPI: 1
Salbutamol inhaled: 3 Salbutamol inhaled: 1
Inhaled steroid: 2 Inhaled steroid: 1
Mean SCAI/HBI score (range; SD) 5.0 (0–14; 4.7) 1.9 (0–7: 1.9) NA
Disease  extent Ileal disease: 8 Left sided: 0 NA
Colonic: 9 Subtotal/pan colonic: 29
Ileo-colonic: 5
Unclear records: 2
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-ASA – aminosalicylate acid, Aza – azathioprine, MP  – mercaptopurine, PPI – proto
apidly developing area within several medical domains [4]. Analy-
is of patients breath using GC–MS (gas chromatography and mass
pectrometry) has revealed VOC patterns which have distinguished
ot just cancer from non-cancer patients but also multiple cancer
ubtypes including lung, breast, prostate and colorectal cancer [5].
rinary VOC patterns have been shown to distinguish between not
nly inﬂammatory bowel disease (IBD) and healthy control patients
ut between active and quiescent disease for both IBD subtypes
sing E-nose and FAIMS [3]. Several other GI conditions have been
emonstrated to be distinguishable by analysis of VOCs includ-
ng pelvic radiotherapy induced side effects; bile acid diarrhoea
BAD); coeliac disease; colorectal cancer (CRC) and non-alcoholic
atty liver diseases (NAFLD), including the distinction of cirrhotics
rom non-cirrhotics [4,6–8].
VOCs have been identiﬁed as being perturbed in many phys-
ological and pathological states, including a variety of diets and
umerous diseases. The exact mechanisms by which VOCs are gen-
rated are the subject of on-going research, but their production in
he gastrointestinal tract is hypothesised to be the direct result of
ermentation of dietary non-starch polysaccharides. This being the
ase, they represent the complex interaction of colonocytes, human
ut microﬂora and invading pathogens [10]. The resultant fermen-
ation products, ‘the fermentome’ [9–12], can exist in the gaseous
hase and are present in exhaled breath, sweat, urine and faeces
4]. Their presence in bodily secretions from sites distant to the GI
ract (sweat, exhaled air and urine) is believed to be possible due to
he alteration of gut permeability afforded by certain disease states,
ncluding IBD [13]. We  believe that VOCs represent a bio-signature
peciﬁc to patients, which can be affected by a variety of factors
ncluding, genetics, disease state and environmental factors, such
s diet.
The aim of our study was to determine whether exhaled VOCs
ould be used to distinguish IBD from healthy controls, and also UC
rom CD, using ﬁeld asymmetric ion mobility spectroscopy (FAIMS)
echnology.
. Materials and methods
.1. SubjectsA total of 76 subjects were recruited prospectively for this study.
ifty-four patients had histologically conﬁrmed IBD (29 UC and 25
D) as well as 22 healthy controls. IBD patients were recruited
rospectively from dedicated IBD clinics at University Hospital3.8 (2.6)
p inhibitor, Anti-TNF – anti tumour necrosis factor alpha.
Coventry & Warwickshire. Details of medication and symptoms
were recorded and simple colitis activity index (SCAI) for UC and
Harvey Bradshaw index (HBI) calculated at time of recruitment.
Along with serological markers of inﬂammation, healthy controls
were volunteers who  did not report any overt gastrointestinal
symptoms and were not on routine oral medication. The mean age
of the IBD cohort was  47 years (standard deviation 15) and there
were 22 males and 34 females. The demographics of the subjects
are shown in Table 1, including disease extent.
2.2. Study design
This was  a case control study, with recruitment of sequential
patients attending an IBD outpatient clinic at University Hospi-
tal Coventry & Warwickshire, UK. Demographic data and disease
activity score indices were collected from the patients.
2.3. Breath sampling
Morning breath samples were taken from both patients and
controls after a minimum of a 2 h fast and absence of cigarette
smoking. The specimens were collected using a 3 L Tedlar® bag
(Thames Restek, UK) which had a ¼′′ OD nozzle tube and threaded
valve for sample capture. A custom made breath capture device
was constructed to allow sampling. The breath capture device
allows patients to breathe naturally through a mouth piece into
the attached Tedlar® bag. The device comprises of a ﬁlter, to ensure
controlled environmental standards for sampling, to which is con-
nected to a 2 way valve. The two way valve allows the patient
to inhale clean air (which ﬁrst passes through the ﬁlter) and
then exhale into the Tedlar® bag. These valves also had custom
made PTFE adaptors attached to allow for connection to disposable
mouthpieces, whilst the other adaptors connect to an additional
three way tap between the exhaled breath path and the Tedlar®
bag. This tap is then attached to the breath bag via disposable tub-
ing and allows for the isolation of end-tidal breath in the bags,
which has higher VOC content. All samples were obtained from
patients directly and placed in a freezer (−20 ◦C) as soon as possi-
ble. The samples were then shipped to the University of Warwick
with a total of 1 h to reach room temperature before analysis
(including the transport time). Once defrosted the sample bags
were attached to the FAIMS via the custom unit as described in
the next section. All samples were tested on the same day as cap-
ture.
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.3.1. FAIMS (ﬁeld asymmetric ion mobility spectroscopy)
Here, a commercial setup was utilised (Lonestar, Owlstone, UK).
his system achieves separation of chemical components on the
asis of differences in molecular mobilities in a high electric ﬁeld.
AIMS allows gas molecules to be separated and analysed at atmo-
pheric pressure and room temperature. Once the sample is ionised,
he resulting ions are passed between two metal plates and then
n asynchronous high voltage waveform is applied to these plates,
ubjecting the ionised molecules to high electric ﬁelds. The differ-
nce in movement of these ions within this high electric ﬁeld can
e measured, thus resulting in a separation of the complex mixture.and (b) a typical breath output from a Crohn’s disease patient.
The Lonestar was modiﬁed with a custom set up designed specif-
ically for breath sampling. This custom made unit comprises an
inlet port for the Tedlar® bags, compressed air running through a
mass-ﬂow controller (MFC) and an external pump on the instru-
ment exhaust. The use of a MFC  allowed for greater control of the
air:sample ratio to optimise the analysis conditions. The ﬂow rate
of the sample was set by controlling the difference between the
pump (set to 1.8 L/min) and the compressed air line (1.5 L/min) this
results in a vacuum and the sample inlet then draws 300 mL/min
of the breath sample into the machine for analysis. Each sample
was run to collect 2 matrices of data, using approximately 2.3 L of
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 and controls (UC – ulcerative colitis, CD – Crohn’s disease, V – volunteer).
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Fig. 3. Receiver operator curve (ROC) plots of IBD (UC and CD) vs healthy controls.Fig. 2. Predictions of classiﬁer to different combinations of diseases
ample. Fig. 1a shows a photo of the capture setup and Fig. 1b an
xample output of a breath sample from a Crohn’s patient.
.4. Statistical methods
Data from the FAIMS equipment were processed using a previ-
usly developed pipeline which has performed well on FAIMS data
n the past [6–8]. The data were pre-processed in an unsupervised
anor by performing a 2D wavelet transformation and using the
avelet coefﬁcients as the new representation of the data. Features
ith small standard deviations (<0.002) were discarded. Super-
ised feature selection and class prediction was performed within
 10-fold cross-validation, where feature selection and classiﬁer
raining was performed on the training set, and class predictions
roduced for the test set. A Wilcoxon rank sum test was used to
alculate p-values for each feature having signiﬁcantly different
istributions between classes, and all but the two most signiﬁcantly
iffering features were discarded. A sparse logistic regression clas-
iﬁer was used to produce the class predictions which are used for
ensitivity and speciﬁcity calculation.
.5. Ethics
Scientiﬁc and ethical approval was obtained from the War-
ickshire Research & Development Department and Warwickshire
thics Committee 09/H1211/38. Written informed consent was
btained from all patients who participated in the study.
. Results
The demographic data of the IBD patient, both UC and CD, and
ealthy control patients are described in Table 1. There was a female
ender predominance overall and this was more marked in the
ontrol group. Previous studies have not shown any effect on VOC
roﬁling by age or gender [4,6–8]. The IBD patients were mainly in
emission (SCAI and HBI scores of 5 and 2 respectively).
We studied the predictive performance of the data from the
AIMS analysis of exhaled breath using a pipeline consisting of
avelet transformation, feature selection and a sparse logistic
egression classiﬁer. This was used to classify samples and calculate
ensitivities and speciﬁcities as part of a 10-fold cross-validation.
ig. 2 shows the predictive power of IBD (UC & CD) vs controls, UC
s controls, CD vs controls and ﬁnally UC vs CD.
The analysis showed that exhaled VOCs were able to distinguish
BD from control patients using breath samples with a sensitivity
f 0.74 (95% conﬁdence intervals (CI): 0.65–0.82) and speciﬁcity ofFig. 4. Receiver operator curve (ROC) of CD vs UC.
0.75 (95% CI: 0.53–0.90), p-value 6.2 × 10−7. The AUROC was 0.82
(95% CI: 0.74–0.89) – Fig. 3.
When analysing the IBD cohort, FAIMS could distinguish those
with UC from those with CD with a sensitivity of 0.67 (95% CI:
0.54–0.79) and speciﬁcity of 0.67 (95% CI: 0.54–0.79), p-value
9.23 × 10−4. The AUROC was 0.70 (95% CI: 0.60–0.80) – Fig. 4.
Table 2 highlights the full set of sensitivities and speciﬁcities and
AUROC numbers with 95% conﬁdence intervals.4. Discussion
Our study provides further evidence of the potential util-
ity of breathomics as a non-invasive and inexpensive means of
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Table  2
Sensitivities and speciﬁcities of FAIMS techniques for distinguishing the IBD patients
from  the healthy control subjects and UC from CD.
Comparison Sensitivity (95% CI) Speciﬁcity (95% CI) AUC (95% CI)
UC & CD vs controls 0.74 0.75 0.82
(0.65–0.82) (0.53–0.90) (0.74–0.89)
UC  vs controls 0.61 0.62 0.70
(0.47–0.73) (0.41–0.81) (0.59–0.81)
CD  vs controls 0.69 0.67 0.77
(0.54–0.81) (0.45–0.84) (0.66–0.88)
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(0.54–0.79) (0.54–0.79) (0.60–0.80)
istinguishing between patients with IBD and healthy controls
y VOC analysis. It also shows some early potential to possibly
istinguish CD from UC, although the sensitivity and speciﬁcity
f 0.67 is currently lower compared to colonoscopy, is still an
mprovement from clinical acumen to distinguish the two  condi-
ions in real time. It expands on previous ﬁndings in breath (using
ifferent technology) as well as studies showing the validity of
rinary VOC smell prints in those with gastrointestinal and liver
iseases [3,4,6–8].
Exhaled VOCs have been demonstrated to be able to distinguish
atients with IBD from healthy controls in paediatric populations.
atel et al., demonstrated that exhaled VOCs could distinguish IBD
rom healthy controls with AUC of 0.96 (95% CI: 0.93–0.99). This was
ndertaken using selective ion ﬂow tube mass spectroscopy (SIFT-
S), with no discernible differences between UC and CD patients,
or was there a correlation with disease activity [14,15]. They found
hat 3 speciﬁc VOCs were implicated (1-octene, 1-decene and (E)-
-nonene). SIFT-MS analysis was also used to distinguish between
D and active UC, with systemic pentane production found to be
redominant. This is thought to reﬂect cellular lipid peroxidation,
hich is a consequence of mucosal inﬂammation [1,16]. Other
tudies have found that mean breath pentane, ethane, propane,
-cotene, 3-metylhexane, 1-decene and nitric oxide levels were
levated and mean breath (E)-2-nonene, hydrogen sulphide and
ethane were decreased in IBD compared with healthy controls
10]. It has also been shown that condensed cytokines in breath are
igher in IBD compared with healthy controls. Levels of exhaled
entane, ethane, propane, isoprene and NO levels have been shown
o correlate with IBD activity, whilst breath condensate interleukin-
B levels were inversely related to clinical disease activity [17].
ore recently exhaled VOC analysis using SIFT-MS has been shown
o distinguish CD and UC from healthy controls in adult patients
AUROCs 0.86 and 0.74 respectively), and CD from UC (AUROC 0.83).
his ROC analysis was conducted using combinations of statistically
igniﬁcant VOCs (dimethyl sulphide, hydrogen sulphide, hydrogen
yanide, ammonia, butanal, and nonanal) [18].
VOCs are believed to be produced by colonic fermentation and
epresent the result of complex interactions between the colono-
yte cells, human faecal ﬂora, mucosal integrity and invading
athogens [10]. The VOCs pass into bodily ﬂuids and as a result,
OCs found in urine, faeces and breath have huge potential as
iomarkers to aid in the assessment of many gastrointestinal dis-
ases. Any changes found in the pattern of VOCs are reﬂective of
hanges and variations within the gastrointestinal environment.
This study to our knowledge is the ﬁrst utilising portable FAIMS
echnology for breath VOC detection in IBD. One of the limitations
f this study is its sample size which was relatively small and we
ave we have not controlled for age or sex but in previous stud-
es (including breath studies) neither of these variables seemed to
ffect VOC proﬁling [4,6–8]. In our protocol we used a two hour fast
hich seemed appropriate in the absence of any evidence or agreed
onsensus as to optimal fasting period prior to breath analysis in
BD.
[
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It should be noted that for FAIMS technology, unlike SIFT-MS, it
is challenging to identify speciﬁc chemicals. Currently, understand-
ing the reactive ion path of speciﬁc chemicals is still in its infancy
and therefore alternative “smell print” approaches provide the best
means of extracting relevant chemical information from the instru-
ment output. Though in some studies SIFT-MS outperforms the
diagnostic power of FAIMS, importantly FAIMS is a fraction of the
price of SIFT-MS (10–20% of the cost), is small, portable and uses
air as the carrier gas [19]. Thus, the value of FAIMS is the poten-
tial for real time separation of VOC proﬁles utilising non-invasive
technology (which is portable, breath analysis can be carried out
at the bedside) to aid in the detection of IBD and distinction of UC
from CD. Though, in this study we do not undertaken direct breath
sampling, developments are in place to facilitate this. Importantly,
our results were also comparable [18].
The nature of the biological samples required for the process is
more likely to be acceptable to patients than other invasive meth-
ods although likely to serve as an adjunct to current methods.
Further validation studies would be required, to conﬁrm the accu-
racy of the technique and determine if it can distinguish active from
quiescent disease, as urine has been demonstrated to be able to do.
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